Skip to main content

Table 3 Incidence of adverse events (intention-to-treat population)

From: Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study

Event, n (%)Nitrous oxide/oxygen plus acetaminophen (n = 340)Morphine (n = 344)
Adverse events in the 30 min after starting treatment
 ≥1 expected adverse event45 (13.2)35 (10.2)
  Respiratory depression (< 10 cycles/min or score ≥ R1)4 (1.2)5 (1.5)
  Nausea (without vomiting)11 (3.2)8 (2.3)
  Vomiting17 (5.0)16 (4.7)
  Sedation (score of ≥2)15 (4.4)7 (2.0)
  Dizziness3 (0.9)3 (0.9)
  Pruritus03 (0.9)
 ≥1 unexpected serious adverse event21 (6.2)12 (3.5)
 Adverse event that led to treatment interruption24 (7.1)4 (1.2)
Serious adverse event in the 30 days after enrolment64 (18.8)55 (16.0)
 Adverse event occurring in ≥1% of patients
  Ventricular tachycardia21 (6.2)5 (1.5)
  Ventricular fibrillation8 (2.4)5 (1.5)
  Cardiogenic shock5 (1.5)7 (2.0)
  Heart failure3 (0.9)5 (1.5)
Death in the 30 days after enrolment6 (1.8)13 (3.8)